Greenwich LifeSciences (NASDAQ:GLSI) Now Covered by Noble Financial

Key Points

• Noble Financial has initiated coverage of Greenwich LifeSciences (NASDAQ:GLSI), assigning it an "outperform" rating and a price target of $45.00, which suggests a potential upside of 289.61% from its current price.
• The company's shares have recently traded around $11.55, with a 52-week low of $8.06 and a high of $16.50, reflecting significant volatility.
• Greenwich LifeSciences is a clinical-stage biopharmaceutical company focusing on developing immunotherapies for HER2/neu-expressing cancers, with its lead candidate, GP2, currently in Phase III clinical trials.

Noble Financial assumed coverage on shares of Greenwich LifeSciences (NASDAQ:GLSI - Free Report) in a research note released on Wednesday, Marketbeat Ratings reports. The firm issued an outperform rating and a $45.00 price target on the stock. Noble Financial also issued estimates for Greenwich LifeSciences' Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.25) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.48) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at $3.98 EPS and FY2029 earnings at $9.90 EPS.

Greenwich LifeSciences Price Performance

NASDAQ:GLSI traded up $0.33 during mid-day trading on Wednesday, reaching $12.18. 37,473 shares of the company's stock traded hands, compared to its average volume of 45,082. Greenwich LifeSciences has a 12-month low of $8.06 and a 12-month high of $16.50. The firm has a market capitalization of $166.01 million, a price-to-earnings ratio of -8.96 and a beta of 1.65. The company has a 50 day moving average price of $10.80 and a 200-day moving average price of $10.57.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.06). As a group, analysts forecast that Greenwich LifeSciences will post -0.8 EPS for the current year.

Institutional Trading of Greenwich LifeSciences

Several large investors have recently bought and sold shares of GLSI. JPMorgan Chase & Co. boosted its position in Greenwich LifeSciences by 172.0% during the 4th quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company's stock valued at $79,000 after acquiring an additional 4,465 shares in the last quarter. Wells Fargo & Company MN boosted its position in Greenwich LifeSciences by 54.8% during the 4th quarter. Wells Fargo & Company MN now owns 2,847 shares of the company's stock valued at $32,000 after acquiring an additional 1,008 shares in the last quarter. Barclays PLC boosted its position in Greenwich LifeSciences by 12.7% during the 4th quarter. Barclays PLC now owns 9,648 shares of the company's stock valued at $108,000 after acquiring an additional 1,088 shares in the last quarter. Northern Trust Corp boosted its position in Greenwich LifeSciences by 17.3% during the 4th quarter. Northern Trust Corp now owns 87,423 shares of the company's stock valued at $982,000 after acquiring an additional 12,923 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in Greenwich LifeSciences by 22.3% during the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock valued at $82,000 after acquiring an additional 1,322 shares in the last quarter. 4.16% of the stock is owned by institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.